Adem Abrham
LinkedIn Copy
Hey Adem — congrats on launching 74 North. Similar IB → PE background here — been deep in healthcare services origination lately. Would be good to connect.
Hey Adem, similar background, weirdly — I'm from Zimbabwe, did growth equity in London, not building a physician-led MSK platform like you. most healthcare services funds I talk to are running on PitchBook or Grata, maybe Affinity, and then basically Excel and email for everything else on the origination side. but proprietary deal flow still feels thin. thesis, network, and intelligence never sync into one system — so origination resets every cycle instead of compounding. does origination look different at 74 North? — Russ
Hey Adem, similar background, weirdly — I'm from Zimbabwe, did growth equity in London, not building a physician-led MSK platform like you. most healthcare services funds I talk to are running on PitchBook or Grata, maybe Affinity, and then basically Excel and email for everything else on the origination side. but proprietary deal flow still feels thin. thesis, network, and intelligence never sync into one system — so origination resets every cycle instead of compounding. does origination look different at 74 North? — Russ
hey Adem — one more thought on origination. after hitting this wall myself doing growth equity, I ended up building origination infrastructure for funds full-time — Mentmore Capital, Axiom Equity, Noble Rock, a few others. at my old fund we had a solid stack and smart people, and origination still restarted from scratch every cycle. the funds who systematise it early end up compounding deal flow — the ones who don't keep resetting. curious if 74 North has cracked that or if it's the same pattern. — Russ
hey Adem — no stress on any of this. we documented the origination infrastructure we've built across funds — tech stack, workflows, prompts. free to share if it'd be useful at 74 North. either way, I'm around if origination ever becomes a conversation worth having. — Russ
Email Copy
Hi Adem, looks like we share a similar PE path — though I'm from Zimbabwe and ended up doing growth equity in London, not building a physician-led MSK platform. most healthcare services funds I talk to are running on PitchBook or Grata, maybe Affinity, and then basically Excel and email for everything else on the origination side. yet the off-market pipeline stays weirdly thin. the intelligence is all there but it's scattered across tools and inboxes — so nothing compounds into a real origination edge. does origination look different at 74 North? Russell searchloop.ai linkedin.com/in/russellt23
hi Adem — been thinking more about origination. after hitting this wall myself doing growth equity, I ended up building origination infrastructure for funds full-time — Mentmore Capital, Axiom Equity, Noble Rock, a few others. the pattern I keep seeing is that the funds who systematise it early end up compounding deal flow in a way that's really hard to replicate later. happy to compare notes on what's actually moving the needle if you're interested. Russell searchloop.ai linkedin.com/in/russellt23
hi Adem — something about this keeps rattling around. when I was doing growth equity we had every subscription going — PitchBook, CRM, enrichment tools, the lot — and I still spent half my time manually pulling origination together across all of it. always wondered if that was just us being disorganised or if it's genuinely universal. imagine 74 North has a way more dialled setup — but figured I'd ask. Russell searchloop.ai linkedin.com/in/russellt23
hi Adem — completely separate from all that. we put together a playbook on PE origination — the tech stack, the workflows, some of the prompts and automations that actually move the needle. happy to send it over if it'd be useful at 74 North. Russell searchloop.ai linkedin.com/in/russellt23
hi Adem — I'll leave it here. the origination playbook is yours whenever — no expiry on that. I'm deep in this space all day, so if it ever becomes a conversation worth having, I'm around. Russell searchloop.ai linkedin.com/in/russellt23
Prospect Research
## PROSPECT INFORMATION: Name: Adem Abrham Title: Managing Partner Fund: 74 North Capital Background: Profile Summary: Adem Abrham Current Role: Managing Partner at 74 North Capital since January 2024, focusing on healthcare investing, specifically within the musculoskeletal (MSK) and orthopedic space. Professional Background: Adem has an extensive career in private equity and investment management. Prior to 74 North Capital, he was a Private Equity Investor at Blue Wolf Capital Partners (2022–2023). He previously served as a Private Equity Summer Associate at FSN Capital Partners in Germany/Norway and worked as a Private Equity Investor at Zoscales Partners focusing on East Africa. Early in his career, he held a position in the Corporate & Investment Bank at JPMorgan Chase & Co. (2014–2018). He holds an MBA from The Wharton School and a B.S. in Molecular Biology/Pre-medicine from Connecticut College. Skills: Financial modeling, valuation, strategic planning, deal structuring, healthcare operations, physician alignment, clinical research, venture capital, and private equity strategy. Key Posts and Hooks for Outreach: Post Date: October 28, 2025 Key Quote: “Emil reflected on lessons from the first wave of orthopedic consolidation, highlighting what succeeded and where things fell short, which are guiding the partnership approach we’re developing under 74 North Capital’s North Star MSK Partners platform.” Context: Adem shared insights from the AAHKS Annual Meeting, specifically regarding physician-led governance, culturally aligned partnerships, and sustainable economic models in orthopedics. He also showcased a hands-on experience demoing the KINCISE™ Surgical Automated System. Post Date: June 24, 2025 Key Quote: “Dr. Engels brings over two decades of experience leading and scaling multi-site healthcare organizations... This unique perspective, having been both a seller and a buyer of physician practices, deeply informs his approach to physician alignment, deal structuring, and post-close execution.” Context: A corporate announcement welcoming Dr. Emil Engels as an Operating Partner, signaling 74 North Capital's commitment to physician-led healthcare services. Post Date: May 23, 2025 Key Quote: “Despite a slowdown in overall Healthcare M&A in ‘23 and ‘24 after post-COVID boom in ‘21 and ‘22, things are opening up in 2025 YTD and there is a lot of (cautious) optimism.” Context: Reflection on his experience at the 21st Annual McGuireWoods LLP Healthcare Private Equity and Finance Conference in Chicago, where he engaged in multiple meetings with PE investors and executives. Fund details: - Description: 74 North Capital is a private investment firm led by a team of skilled investors and seasoned operators. We specialize in acquiring and enhancing companies with proven performance and significant growth prospects. We focus on collaborating with existing management and leveraging our broad network of industry experts to help companies reach new growth milestones. - Website: https://74northcapital.com - Location: New York, New York, United States - Lead qualification: Research: - Query: =74 North Capital Adem Abrham recent investments fund thesis - Answer: 74 North Capital focuses on physician-led healthcare services, particularly in orthopedic care. Adem Abrham is associated with the firm and has invested in medical devices. The firm's investment thesis emphasizes building a platform in orthopedic care delivery.